International Assets Investment Management LLC Grows Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

International Assets Investment Management LLC grew its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 1,098.4% during the third quarter, HoldingsChannel.com reports. The fund owned 4,494 shares of the company’s stock after purchasing an additional 4,119 shares during the quarter. International Assets Investment Management LLC’s holdings in Nurix Therapeutics were worth $101,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Acadian Asset Management LLC grew its stake in shares of Nurix Therapeutics by 576.7% in the first quarter. Acadian Asset Management LLC now owns 160,293 shares of the company’s stock valued at $2,355,000 after buying an additional 136,606 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Nurix Therapeutics by 365.0% during the second quarter. SG Americas Securities LLC now owns 103,199 shares of the company’s stock valued at $2,154,000 after purchasing an additional 81,005 shares during the period. Renaissance Technologies LLC lifted its position in shares of Nurix Therapeutics by 80.7% during the second quarter. Renaissance Technologies LLC now owns 324,000 shares of the company’s stock worth $6,762,000 after purchasing an additional 144,700 shares in the last quarter. TD Asset Management Inc purchased a new position in shares of Nurix Therapeutics in the second quarter valued at $593,000. Finally, Candriam S.C.A. grew its holdings in Nurix Therapeutics by 30.5% during the 2nd quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock valued at $24,297,000 after purchasing an additional 272,136 shares in the last quarter.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.22, for a total transaction of $504,400.00. Following the sale, the chief financial officer now owns 31,002 shares of the company’s stock, valued at approximately $781,870.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CFO Houte Hans Van sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.22, for a total value of $504,400.00. Following the sale, the chief financial officer now directly owns 31,002 shares in the company, valued at $781,870.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,437 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $83,519.10. Following the transaction, the insider now owns 50,670 shares of the company’s stock, valued at $1,231,281. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 57,321 shares of company stock valued at $1,414,409 in the last ninety days. Company insiders own 9.80% of the company’s stock.

Wall Street Analysts Forecast Growth

NRIX has been the topic of a number of recent analyst reports. Stephens reiterated an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Monday, October 14th. Barclays increased their price target on Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, July 15th. UBS Group started coverage on Nurix Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $35.00 price objective on the stock. Royal Bank of Canada reduced their target price on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Finally, Oppenheimer lifted their price target on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.40.

Nurix Therapeutics Trading Up 0.9 %

NASDAQ:NRIX opened at $27.24 on Friday. The stock has a 50 day moving average of $24.26 and a 200-day moving average of $20.55. The firm has a market capitalization of $1.93 billion, a PE ratio of -9.51 and a beta of 2.20. Nurix Therapeutics, Inc. has a 52 week low of $4.96 and a 52 week high of $28.42.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). The firm had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, analysts predict that Nurix Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.